In T lymphocytes, the mitogen-activated protein kinase (MAPK) p38 regulates pleiotropic functions and is activated by canonical MAPK signaling or the alternative activation pathway downstream of the T cell antigen receptor (TCR). Here we found that senescent human T cells lacked the canonical and alternative pathways for the activation of p38 but spontaneously engaged the metabolic master regulator AMPK to trigger recruitment of p38 to the scaffold protein TAB1, which caused autophosphorylation of p38. Signaling via this pathway inhibited telomerase activity, T cell proliferation and the expression of key components of the TCR signalosome. Our findings identify a previously unrecognized mode for the activation of p38 in T cells driven by intracellular changes such as low-nutrient and DNA-damage signaling (an 'intrasensory' pathway). The proliferative defect of senescent T cells was reversed by blockade of AMPK-TAB1-dependent activation of p38.
T cell proliferative responses are essential for the lifelong preservation of adaptive immunity. Optimal activation of T cells requires both engagement of the T cell antigen receptor (TCR) and costimulatory signals 1 ; however, progressive loss of the costimulatory receptors CD27 and CD28 occurs during the end-stage differentiation of T cells toward senescence that correlates well with loss of proliferation 2 . The mechanisms that regulate the loss of proliferative potential in highly differentiated T cells are poorly understood. The aim of this study was to identify mechanisms involved in the end-stage differentiation of human T cells and whether intervention is possible to restore proliferative activity in these cells.
The loss of surface CD27 followed by loss of CD28 expression during the differentiation of human CD4 + T cells 3 enables the identification of undifferentiated T cells that have high proliferative activity and the longest telomeres (CD27 + CD28 + ); intermediate differentiated cells that have reduced proliferation and telomeres of intermediate length (CD27 − CD28 + ); and end-stage or senescent T cells that proliferate poorly and have the shortest telomeres (CD27 − CD28 − ) 3 . Senescent CD27 − CD28 − CD4 + T lymphocytes accumulate substantially in old humans and in patients with chronic viral infections and those with autoimmune disorders [3] [4] [5] [6] [7] . The senescence characteristics of these cells include short telomeres, low telomerase activity and reduced proliferative capability 8 that is due in part to a spontaneous but unexplained increase in activity of the mitogen-activated protein kinase (MAPK) p38 (ref. 9) . Nevertheless, CD27 − CD28 − CD4 + T cells exhibit potent effector functions and cannot be viewed as a dysfunctional population per se [3] [4] [5] [6] [7] . Here we investigated the regulatory network upstream of p38 in the senescent CD27 − CD28 − CD4 + T cell subset. The p38 family comprises the p38α, p38β, p38γ and p38δ isoforms that regulate many different functions in a cell-typeand stimulus-dependent manner 10 . T lymphocytes express mainly the p38α isoform and, to a lesser extent, the p38β and p38δ isoforms 10 . The canonical MAPK cascade is the main mechanism for the activation of all four p38 isoforms in mammalian cells, including T cells [10] [11] [12] . Signaling through the MAPK pathway activates p38 by dual phosphorylation at Thr180 and Tyr182 in response to environmental stress, inflammation, DNA damage 12 and also the engagement of costimulatory receptors 13 . In addition, T cells have an alternative pathway for the activation of p38 in which antigenic stimulation via the TCR induces phosphorylation of p38α and p38β at Tyr323 by TCR-proximal tyrosine kinases 14 , followed by autophosphorylation at Thr180 and Tyr182 (ref. 14) .
We found here that instead of using the canonical or alternative pathway, freshly isolated CD27 − CD28 − CD4 + T lymphocytes engaged a distinct mechanism whereby the intracellular metabolic sensor AMPK triggered autophosphorylation of p38 via the scaffold protein TAB1. Furthermore, signaling through this pathway downregulated the expression of central components of the TCR signalosome, a previously unidentified characteristic of T cell senescence. Activation of p38 through AMPK-TAB1 was induced not only by endogenous DNA damage but also by a decrease in intracellular concentrations of glucose. Thus, unlike the canonical and alternative pathways for the activation of p38 that respond to external cues (for example, cytokines or activation of the TCR), T cells have an 'intrasensory' pathway for the activation of p38 that senses intracellular changes, such as glucose deprivation and genotoxic stress. Once triggered, this 9 6 6 VOLUME 15 NUMBER 10 OCTOBER 2014 nature immunology A r t i c l e s pathway inhibits T cell proliferation and telomerase activation via p38 signaling, and this can be reversed by inhibition of AMPK, TAB1 or p38 itself.
RESULTS p38 activation without canonical or alternative pathways
The relative expression of CD27 and CD28 identified three distinct populations in primary human CD4 + T cells (Fig. 1a) . CD27 − CD28 − T cells are known to exhibit low telomerase and proliferative activity upon activation 3 , which are characteristics of end-stage differentiation or senescence 3, 4, 9, 15 . The CD27 − CD28 − subset of CD4 + T cells also exhibited endogenously elevated (spontaneous) phosphorylation of p38 (at Thr180 and Tyr182) that was significantly (2-to 2.5-fold) higher than that of the CD27 + CD28 + or CD27 − CD28 + T cell subset in vivo (Fig. 1b) .
We investigated whether the canonical MAPK cascade, which regulates the activation of p38 in response to stress stimuli and the engagement of costimulatory receptors 12, 13 , was responsible for the endogenous activation of p38 observed in CD27 − CD28 − CD4 + T cells. Freshly isolated human CD27 − CD28 − CD4 + T cells did not express or activate either MKK3 or MKK6 (Fig. 1c,d ), the direct upstream regulators of p38 in this signaling cascade 12 . Similarly, these cells did not activate MKK4 (data not shown), an activator of the MAPK Jnk 16 that in some conditions may also activate p38 (ref. 10) . Furthermore, the phorbol ester PMA, a well-established agonist of the canonical MAPK cascade 17 , failed to enhance p38 activity in CD27 − CD28 − CD4 + T cells but induced a significant increase in the phosphorylation of p38 in the undifferentiated CD27 + CD28 + subset (Fig. 1e,f) . We made similar observations when we induced the canonical p38 pathway with the osmotic stressor sorbitol (data not shown). Thus, despite the constitutive increase in p38 activity (Fig. 1b) , human senescent CD27 − CD28 − CD4 + T cells did not regulate p38 signaling by the canonical MAPK cascade.
Antigenic stimulation through the TCR activates p38 by an alternative pathway in which a tyrosine kinase cascade that is dependent on the kinase Lck and is mediated by the signaling kinase Zap70 phosphorylates p38 at Tyr323 (ref. 14) . The membrane-associated scaffold molecule DLG1 binds p38 and coordinates this process 18 . Because persistent antigenic stimulation drives the differentiation of human T cells in vivo 2, 3 , we investigated whether the alternative pathway for the activation of p38 via TCR signaling was responsible for inducing p38 signaling in CD27 − CD28 − CD4 + T cells. However, we found that the CD27 − CD28 − CD4 + population did not phosphorylate p38 on the alternative Tyr323 site before or after stimulation with antibody to the invariant signaling protein CD3 (anti-CD3) (Fig. 1g) . In contrast, undifferentiated CD27 + CD28 + CD4 + T cells had abundant phosphorylation of p38 at Tyr323 upon activation with anti-CD3 (Fig. 1g) .
We next investigated expression of elements of the TCR signalosome that constitute the alternative pathway for p38 activation in CD27 + CD28 + , CD27 − CD28 + and CD27 − CD28 − CD4 + T cells. We found that in contrast to the CD27 + CD28 + and CD27 − CD28 + CD4 + subsets, freshly isolated CD27 − CD28 − CD4 + T cells did not express Lck, Zap70 or DLG1 (Fig. 1h,i) . In addition, these cells also lacked other essential downstream components of the TCR signaling machinery, such as the adaptors Lat and SLP-76, and had very low expression of the phospholipase PLC-γ1 ( Supplementary Fig. 1a,b) . The loss of TCR signaling machinery in senescent CD27 − CD28 − CD4 + c CD27 CD28 
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A r t i c l e s T cells was also associated with defective calcium influx upon stimulation with anti-CD3 ( Supplementary Fig. 1c,d ), which indicated that the loss of TCR signaling molecules impaired TCR responsiveness. Together these data indicated that the spontaneous increase in p38 activity observed in CD27 − CD28 − CD4 + T cells was not regulated by either the canonical MKK signaling pathway or the alternative TCR-mediated signaling pathway, in contrast to the regulation of p38 in nonsenescent CD4 + T cells 11, 19 .
p38 activation is triggered by AMPK and mediated by TAB1 In HEK293 human embryonic kidney cells, allosteric autophosphorylation of p38 at Thr180 and Tyr182 is induced independently of upstream MKKs via the scaffold molecule TAB1 (ref. 20) . We investigated whether TAB1 signaling was involved in the constitutive activation of p38 observed in senescent CD27 − CD28 − CD4 + T cells. Two TAB1 splice variants (α or β, with a molecular mass of 60 kilodaltons (kDa) or 50 kDa, respectively) bind to and activate p38 by an identical mechanism 21 . Using a monoclonal antibody directed against the p38-binding domain common to both isoforms, we found that CD27 − CD28 − CD4 + T cells expressed the 50-kDa isoform of TAB1 (Fig. 2a) , which does not bind to or regulate the kinase TAK1, its binding partner 21 . In addition, CD27 − CD28 − CD4 + T cells also did not express TAK1 itself (Fig. 2a) . Conversely, nonsenescent T cell subsets expressed TAK1 and also full-length TAB1, which binds to TAK1 (Fig. 2a) . Because activation of the TAB1 pathway requires nondegradative ubiquitination by the upstream E3 ubiquitin ligase TRAF6 (ref. 20) , we examined the expression of TRAF6 in the nonsenescent and senescent CD4 + T cell subsets. CD27 − CD28 − CD4 + T cells lacked TRAF6 expression (Fig. 2a) , which indicated that the TRAF6-TAK1 pathway was not active in these cells. AMPK is activated in response to low intracellular concentrations of glucose, and activated AMPK has been shown to bind to TAB1 in ischemic mouse cardiomyocytes 22 . This molecule is activated by phosphorylation at Thr172 in its catalytic α-subunit to shift metabolism toward catabolic reactions 23 . In addition, AMPK inhibits mTOR activity in T cells 24, 25 . We investigated whether AMPK regulated p38 activity in CD27 − CD28 − CD4 + T cells via TAB1. Freshly isolated human CD27 + CD28 + , CD27 − CD28 + and CD27 − CD28 − CD4 + T cells all expressed AMPKα, but only the CD27 − CD28 − CD4 + T cell subset showed spontaneous activation of AMPK (phosphorylation of AMPKα; Fig. 2b ). To determine whether AMPK was acting upstream of p38 in T cells, we treated CD27 + CD28 + CD4 + T cells, which had no baseline AMPK activity ( Fig. 2b) and exhibited low spontaneous phosphorylation of p38 (Fig. 1b) , with A-769662, a selective agonist of AMPK 26 . This agonist induced significant phosphorylation of p38 at Thr180 and Tyr182 in CD27 + CD28 + CD4 + T cells (Fig. 2c,d ). Despite the high baseline p38 activity of senescent CD27 − CD28 − CD4 + T cells, A-769662 also enhanced phosphorylation of p38 at Thr180 and Tyr182 in these cells (data not shown).
To directly investigate the role of signaling via TAB1 and AMPK in the activation of p38, we used lentiviral vectors (pseudotyped with glycoprotein G of vesicular stomatitis virus) coexpressing a reporter gene encoding green fluorescent protein (GFP) and short hairpin RNA (shRNA) targeting either the catalytic α-subunit of AMPK (shAMPKα) or a region common to both the 60-and 50-kDa isoforms of TAB1 (shTAB1) (Supplementary Fig. 2a-d) . We used an irrelevant vector expressing shRNA with a scrambled sequence (shCtrl) as control ( Supplementary Fig. 2c,d ). We transduced isolated CD27 − CD28 − CD4 + T cells with these vectors 48 h after activating the cells with anti-CD3 and recombinant human interleukin 2 (IL-2). At 4 d after transduction, we examined changes in the phosphorylation of p38 at Thr180 and Tyr182 in GFP + T cells by phosphorylationspecific flow cytometry (Fig. 2e) . Under steady-state conditions, GFP + T cells in which expression of either AMPKα or TAB1 was silenced had significantly lower p38 activity than that of cells transduced with shCtrl ( Fig. 2e) , which indicated that both AMPK and TAB1 regulated the activation of p38 in senescent human CD4 + T cells. 

A r t i c l e s
We next transduced CD27 − CD28 − CD4 + T cells with shCtrl, shTAB1 or shAMPKα and treated them for 1 h with the AMPK agonist A-769662, followed immediately by analysis of the activation of p38 in GFP + T cells by phosphorylation-specific flow cytometry (Fig. 2f,g ). The AMPK agonist-induced activation of p38 was inhibited in the CD27 − CD28 − CD4 + T cells (Fig. 2f,g ), which confirmed that this process was AMPK dependent. The AMPK agonistinduced activation of p38 was also inhibited in CD27 − CD28 − CD4 + T cells transduced with shTAB1 (Fig. 2h,i) ; this indicated that AMPK required TAB1 to activate p38 in these cells. Silencing of the expression of either AMPKα or TAB1 in AMPK agonist-activated CD27 − CD28 − CD4 + T cells also inhibited phosphorylation of the p38 substrate ATF2 at residue Thr71 (Fig. 2h,i) . Similarly, agonist-driven activation of AMPK failed to activate p38 in CD27 + CD28 + CD4 + T cells in which expression of either AMPKα or TAB1 was silenced (data not shown). Thus, activation of AMPK induced p38 signaling in a TAB1-dependent way in senescent human CD4 + T cells.
DNA-damage and low-nutrient sensing by AMPK activates p38
Cellular AMPK is activated mainly in response to decreased intracellular ATP 23 . However, we did not find a lower cellular concentration of ATP in freshly isolated senescent human CD27 − CD28 − CD4 + T cells than in the CD27 + CD28 + or CD27 + CD28 − subset (data not shown). Because only end-stage-differentiated CD27 − CD28 − CD4 + T cells exhibited spontaneous AMPK activity, we investigated whether various end-stage-differentiation features of these cells triggered activation of AMPK. We found evidence of endogenous DNA damage 27 in CD27 − CD28 − CD4 + T cells, including spontaneous phosphorylation of ATM, an apical kinase involved in the DNA-damage response, at residue Ser1921 (Fig. 3a,b) , and of its downstream target γ-H2AX at Ser139 (Fig. 3c,d) , which has been used as an indicator of active DNA-damage foci 28 . Inhibition of ATM activity for 1 h by the selective ATM inhibitor KU-55933 inhibited constitutive phosphorylation of AMPKα at Thr172 and of p38 at Thr180 and Tyr182 in CD27 − CD28 − CD4 + T cells (Fig. 3e-h) , which indicated that ATM acted 'upstream' of both molecules in these cells. We also found a greater abundance of reactive oxidative species (ROS) in these cells ( Supplementary  Fig. 3a) . Because genotoxic stress by ROS induces DNA damage 29 and because ROS are a known activator of AMPK 30 , we assessed the effect of the ROS scavenger superoxide dismutase on the activation of ATM, AMPK and p38. Such scavenging of ROS impaired the activation of all three molecules in CD27 − CD28 − CD4 + T cells (Supplementary Fig. 3b,c) , which suggested that ROS may have triggered the endogenous DNA-damage response that led to the activation of p38 in senescent human T cells.
Because AMPK acts as a sensor of low glucose concentrations in cells 23, 24 , we investigated whether deprivation of glucose also induced the AMPK-dependent activation of p38 in nonsenescent T cells with intact DNA and low ROS production (Fig. 3a-d and Supplementary  Fig. 3a) . Depriving cells of glucose resulted in enhanced phosphorylation of p38 in undifferentiated CD27 + CD28 + CD4 + T cells (Fig. 3i,j) . Following glucose deprivation, the phosphorylation of p38 was inhibited more effectively in cells transduced with shAMPKα or shTAB1 than in cells transduced with shCtrl (Fig. 3k,l) . Together these data supported a model in which signals from both genotoxic pathways and nutrient-deprivation pathways converged at the point of AMPK in T cells, which subsequently activated p38 through TAB1.
AMPK recruits p38 to TAB1 and causes p38 autophosphorylation To further delineate the mechanistic details of the AMPK-TAB1-p38 pathway, we performed immunoprecipitation studies of primary human CD27 + CD28 + CD4 + T cells activated by the AMPK agonist A-769662. We coimmunoprecipitated proteins from these cells with anti-TAB1, followed by immunoblot analysis, and found that npg agonist-driven activation of AMPK promoted the recruitment of p38 to TAB1 by 2.5-to 3-fold (Fig. 4a,b) . Furthermore, the proteins coimmunoprecipitated with anti-TAB1 showed specific enrichment for phosphorylated AMPKα and p38 (Fig. 4a) , which suggested the existence of an active AMPK-TAB1-p38 complex. Similarly, the proteins coimmunoprecipitated from glucose-deprived, undifferentiated CD27 + CD28 + CD4 + T cells with anti-TAB1 also showed enrichment for phosphorylated AMPKα and p38 (data not shown). Notably, activated AMPKα and p38 were constitutively present among proteins coimmunoprecipitated from CD27 − CD28 − CD4 + T cells with anti-TAB1 (Fig. 4c) ; in these cells, the AMPK-TAB1-p38 pathway was constitutively active (as shown above). Because TAB1 mediates autophosphorylation of p38 (ref. 20) , a modification that relies on the intrinsic activity of the kinase, and because p38 is not a direct substrate for AMPK, these data suggested that AMPK may have induced autophosphorylation of p38 by eliciting its binding to TAB1. We therefore used anti-p38 to immunoprecipitate p38 from AMPK agonist-activated CD27 + CD28 + CD4 + T cells transduced with shCtrl, shTAB1 or shAMPKα and assessed the kinase activity of p38 in the absence of an added substrate in vitro to analyze autophosphorylation of p38, as described 14, 18 . With this assay, we detected activated p38 in immunoprecipitates of CD27 + CD28 + CD4 + T cells transduced with shCtrl, and this activity was enhanced by the addition of ATP in vitro (Fig. 4d) . Conversely, the addition of ATP to proteins coimmunoprecipitated with anti-p38 from CD27 + CD28 + CD4 + T cells transduced with shTAB1 or shAMPKα did not increase p38 activity in vitro (Fig. 4d) . This indicated that the autophosphorylation of p38 required AMPK and TAB1 to form a complex together, with which p38 interacted in response to activation by AMPK.
To confirm that the results presented above were indicative of autophosphorylation of p38 (and not an event mediated by an unrelated kinase coimmunoprecipitated with p38), we added the ATP competitor SB-203580, which acts as an inhibitor of p38, directly to the in vitro kinase reaction itself. SB-203580 prevented the enhanced phosphorylation of p38 in vitro in response to exogenous ATP (but not the baseline kinase activation in the cells) among proteins coimmunoprecipitated with anti-TAB1 from CD27 + CD28 + CD4 + T cells after activation by AMPK (Fig. 4e) . We obtained similar results with BIRB 796, a different inhibitor of p38 activity (data not shown). Thus, the p38 recruited to the AMPK-TAB1 complex autophosphorylated itself.
Silencing of AMPKa or TAB1 restores proliferation
Loss of telomerase activity in senescent T cells 3, 8, 15 limits their proliferative potential after antigenic challenge both in vitro and in vivo 31, 32 and is mediated in part by activation of p38, as shown by 'rescue' with a p38-selective small-molecule inhibitor 9, 33 . To determine whether silencing of TAB1 or AMPKα restored these functions in senescent T cells, we transduced activated, purified CD27 − CD28 − CD4 + T cells with shAMPKα or shTAB1 (Supplementary Fig. 4a ). Because the activity of telomerase in T lymphocytes specifically requires re-expression of its catalytic subunit hTERT upon activation 34 , we measured hTERT expression by both immunoblot analysis and quantitative PCR. The expression of hTERT was significantly higher in CD27 − CD28 − CD4 + T cells transduced with shAMPKα or shTAB1 than in cells transduced with shCtrl, as assessed 1 week after activation with anti-CD3 and recombinant human IL-2 (Fig. 5a) ; this led to increased telomerase activity in these cells at the 1-week time point, as assessed by a telomeric repeat-amplification protocol (Fig. 5b) .
To assess the in vivo effect of enhanced telomerase activity in CD27 − CD28 − CD4 + T cells in which expression of either TAB1 or AMPKα was silenced, we measured telomere length by fluorescence in situ hybridization coupled to flow cytometry, as described 15 . Four weeks after transduction of shCtrl, shTAB1 or shAMPKα (Supplementary Fig. 4a) , knockdown of either TAB1 or AMPKα induced a significant extension of telomeric length (0.5-0.7 kilobases) in the GFP + CD27 − CD28 − CD4 + T cells compared with that of cells transduced with shCtrl (Fig. 5c,d) . Furthermore, transduction of shTAB1 or shAMPKα significantly enhanced the short-term (Fig. 5e-g ), as well as their long-term expansion capacity (after 30 d in culture) (Fig. 5h) , compared with that of cells transduced with shCtrl. As a control, inhibition of p38 by p38-specific shRNA or by blockade with either of two different specific inhibitors (BIRB 796 or SB203580) resulted in enhanced telomerase activity and short-term and long-term proliferation of senescent T cells (Supplementary Fig. 4b-g and data not shown) , which confirmed the results of published studies 9 . Thus, the defective proliferation and telomerase activity of human senescent T cells was reversed by the inhibition of AMPK and TAB1 upstream of p38.
To further delineate the role of p38 activation in the proliferation of human senescent T cells, we investigated the effect of p38 on the cellcycle machinery. Because blockade of p38 increased the rate of DNA synthesis (an event that characterizes actively cycling cells in S phase), we activated CD27 − CD28 − CD4 + T cells with anti-CD3 and recombinant human IL-2 and investigated the expression of several factors that regulate the transition from G1 phase to S phase. Inhibition of p38 induced coordinated downmodulation of the cell-cycle inhibitors p27 and p21, upregulation of the D cyclins, enhanced inactivation of the transcription factor Rb (by lowering the abundance of active, underphosphorylated Rb) and dampened activation of the tumor suppressor p53 (Supplementary Fig. 5 and data not shown), which are all well-established events that promote the G1-to-S transition 35 . 
A r t i c l e s
We also obtained similar results when we 'tuned' p38 activity by silencing the expression of either AMPKα or TAB1 via transduction of shRNA in CD27 − CD28 − CD4 + T cells (data not shown), which indicated that the activation of p38 induced by AMPK-TAB1 signaling inhibited cell-cycle progression at the G1-to-S checkpoint. These data suggested that p38 activated by AMPK-TAB1 inhibited T cell proliferation by direct inhibition of cyclins, induction of cyclin inhibitors and downstream activation of p53.
p38 activation induces senescence characteristics in nonsenescent T cells To further link the AMPK-TAB1 pathway to the spontaneous activation of p38, we activated nonsenescent CD27 + CD28 + CD4 + T cells with the AMPK agonist A-769662 in the presence or absence of the selective p38 inhibitor BIRB 796. A-769662 inhibited the telomerase activity, proliferation and population expansion of CD27 + CD28 + CD4 + T cells activated with anti-CD3 and anti-CD28, while the addition of BIRB 796 restored these functions (Fig. 6a,b and data not shown). We obtained similar results in CD27 + CD28 + CD4 + T cells in which expression of p38 was silenced via shRNA ( Supplementary  Fig. 6a,b) . All these observations were reproduced in glucosedeprived CD27 + CD28 + CD4 + T cells, and they were counteracted in part by inhibition of p38 ( Supplementary Fig. 6c-e) . However, cells did not survive the prolonged absence of glucose after 5 d (ref. 36) (data not shown). In addition, activation of AMPK by the agonist A-769662 induced a dose-dependent loss of TCR signaling molecules in CD27 + CD28 + CD4 + T cells activated with anti-CD3 and anti-CD28 (Fig. 6c and data not shown) , and this was prevented in part by inhibition of p38 (Fig. 6d) . Together these data showed that AMPK inhibited the proliferation of human T cells and telomerase via activation of p38, a process that required its allosteric binding to TAB1. Furthermore, nonsenescent T cells activated p38 and downregulated the proliferation and telomerase activity when AMPK was activated chemically or by glucose deprivation.
DISCUSSION
In this study we investigated the mechanism by which p38 is activated in senescent human CD4 + T cells. In T cells, activation of p38 has been documented as being induced either by the canonical MAPK cascade or the alternative TCR signaling pathway in response to environmental stress or TCR activation, respectively 10, 11, 19 . Here we found that senescent human CD4 + T cells lacked essential 'upstream' components of both the canonical pathway and the alternative pathway and instead activated p38 by a previously unrecognized mechanism dependent on AMPK-TAB1. This occurred in vivo in response to endogenous signaling of a DNA-damage response by the apical kinase ATM, in response to genotoxic stress. However, glucose deprivation also triggered the energy gauge AMPK and led to activation of p38 via the scaffold protein TAB1 in nonsenescent CD4 + T cells that had no DNA damage. Therefore, signaling through this AMPK-TAB1 pathway for p38 activation was induced in undifferentiated T cells by low nutrient availability or in senescent T cells by DNA damage. This led to the downregulation of key signaling molecules of the TCR complex and inhibition of both telomerase activity and proliferation.
The scaffold molecule TAB1 was initially identified as a TAK1 binding partner 37 . Subsequently, it was found that TAB1 also induces allosteric autophosphorylation of p38 in the HEK293 cell line independently of TAK1 (refs. 20,21) . However, the biological relevance of TAB1-dependent activation of p38 has remained uncertain. In a model of mouse ischemic cardiomyocytes, both TAB1 and AMPK were reported to act upstream of p38 (ref. 22 ), but two subsequent studies with the same experimental system have challenged that earlier report 38, 39 . The reason for the evolution of different modes for the activation of p38 remains unknown, but our findings suggest that they may enable the same signaling molecule to exert opposite effects on T cell function. We confirmed the published observation that 'alternative' DLG1-mediated activation of p38 downstream of the TCR supports proliferative activity in nonsenescent CD4 + T cells 17, 18 ; however, p38 activated via AMPK-TAB1 inhibited the proliferation of both senescent human CD4 + T cells and nonsenescent human CD4 + T cells. Furthermore, a published report has shown that p38 activated by a 'canonical' pathway and p38 activated by an 'alternative' pathway counter-regulate each other in controlling the effector functions of T cells by exerting different substrate specificity 40 . Also, we note that the mapped TAB1-p38 interaction site 41 impedes access to the 'alternative' regulatory phosphorylation site of p38 at Tyr323, which suggests that scaffold molecules may also be involved in the determination of downstream substrate specificity.
One unexpected observation was that key components of the TCR signaling machinery, such as Lck, Zap70, DLG1, Lat and SLP-76, were naturally lost in senescent CD4 + T cells, which also lose expression of CD27 and CD28 (refs. 8,35) . Collective loss of these signaling molecules would exacerbate the inhibition of proliferation of these cells by decreasing their capacity for TCR activation. Of note, blocking p38 in highly differentiated T cells did not restore expression of the TCR signalosome (data not shown), which suggested that other p38-independent mechanisms were involved.
At present, p38 inhibitors have been developed for use in treating diseases with an inflammatory etiology 42 . When tested in clinical trials, those compounds have shown a low therapeutic index and engagement of escape or bypass mechanisms; the latter effect is possibly due to the regulation of diverse cellular functions by p38 activation 42 . Because inhibition of p38 activity by silencing of the expression of either AMPK or TAB1 in vitro enhanced the proliferation of human T cells, we suggest the possibility of specific inhibition of this pathway as a strategy for enhancing the function of cells of the immune system in vivo. The crystal structure of the docking site for TAB1 on p38 has been reported 41 and is conserved in both the 60-kDa and 50-kDa variants of TAB1 (ref. 21) . Targeting this restricted, MKK-independent interaction may provide a selective way for dampening p38 activity, as it would spare ubiquitous activation by the MAPK cascade 10 . One caveat is that the enhancement of telomerase and proliferation in highly differentiated T cells that have evidence of DNA damage may be tumorigenic 35 . The risk versus possible benefit of selective therapeutic 'tuning' of telomerase in human T lymphocytes in vivo remains to be determined.
We have therefore described an 'intrasensory' pathway in T cells that integrates nutrient deprivation and DNA-damage-sensing signals to activate p38. This may be the prototype of diverse convergent signaling pathways that link senescence, immunomodulation, metabolism and cancer. It is possible that AMPK-TAB1 signaling may be involved with the activation of p38 that is associated in the senescence of various cell types, such as fibroblasts and stem cells from skeletal muscle, in both mice and humans 43, 44 ; this will require further study.
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Methods and any associated references are available in the online version of the paper. 
